Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1

Interventions

nilotinib 6bosutinib 4asciminib 3Imatinib Mesylate 3Decitabine 3decitabine and cedazuridine drug combination 2cedazuridine 2avapritinib 2Dasatinib 2Cytarabine 2Azacitidine 2treosulfan 1trametinib 1tagraxofusp 1pemigatinib 1olutasidenib 1luspatercept 1ivosidenib 1imetelstat 1glasdegib 1enasidenib 1dabrafenib 1GRN163L peptide 1Emapalumab 1Daunorubicin 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × decitabine and cedazuridine drug combination × Myeloid × Clear all
NCT02103478 2024-08-27

Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)

Astex Pharmaceuticals, Inc.

Phase 1/2 Completed
130 enrolled 34 charts 1 FDA
Myeloid

Myelodysplastic Syndromes

NCT03306264 2024-08-27

Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML

Astex Pharmaceuticals, Inc.

Phase 3 Completed
227 enrolled 37 charts 1 FDA
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡